Skip to main content
SpringerLink
Log in

Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and cyclosporine A (CsA) is currently the standard treatment for patients with severe aplastic anemia (SAA) who have no suitable donor or are ineligible for allogeneic stem cell transplantation. However, the delayed hematopoietic recovery, which accounts for most early deaths, remains a key problem. Thus, we designed an IST protocol with fludarabine, rabbit ATG, and CsA followed by unrelated cord blood (UCB) infusion to study whether hematopoiesis could be accelerated. Nineteen patients were enrolled in this study. The median neutrophil recovery time was 22 days and the treatment-related mortality within 3 months was 5.3%. The median platelet recovery time was 180 days. Six patients had transient or sustained UCB engraftment and the median platelet recovery time of these patients was significantly shorter than those who had no UCB engraftment (46 days vs 206 days, p = 0.006). The cumulative incidence of response rate at 12 months was up to 88.7% with CR rate of 72.2%. The overall survival at 2 years and 5 years was 94.7% and 78.9%, respectively. These results suggest that UCB infusion may play an important role in accelerating hematopoietic recovery in this protocol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia. Int J Hematol. 2013;97:564–72.

    Article  CAS  Google Scholar 

  2. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anemia. Br J Haematol. 2016;172:187–207.

    Article  Google Scholar 

  3. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporin as treatment for severe aplastic anemia. Blood. 1995;85:3058–65.

    Article  CAS  Google Scholar 

  4. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood. 2000;95:1931–4.

    Article  CAS  Google Scholar 

  5. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130–5.

    Article  CAS  Google Scholar 

  6. Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica. 2009;94:310–2.

    Article  Google Scholar 

  7. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, cyclosporin and mycophenolate mofetil. Br J Haematol. 2006;133:606–11.

    Article  CAS  Google Scholar 

  8. Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009;94:348–54.

    Article  CAS  Google Scholar 

  9. Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010;115:2136–41.

    Article  CAS  Google Scholar 

  10. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed and refractory severe acquired aplastic anemia. Blood. 2012;119:345–54.

    Article  CAS  Google Scholar 

  11. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430–8.

    Article  CAS  Google Scholar 

  12. Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as frst-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2010;89:851–9.

    Article  CAS  Google Scholar 

  13. Liu HL, Sun ZM, Geng LQ, Wang XB, Ding KY, Tang BI, et al. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced intensity conditioning: high graft rejection, but good survival. Bone Marrow Transplant. 2012;47:1186–90.

    Article  CAS  Google Scholar 

  14. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988;70:177–82.

    Article  CAS  Google Scholar 

  15. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43–70.

    Article  CAS  Google Scholar 

  16. Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Eom KS, et al. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a frst-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2013;92:817–24.

    Article  CAS  Google Scholar 

  17. Li X, Shi J, Ge M, Shao Y, Huang J, Huang Z, et al. Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience. PLoS ONE. 2013;8(3):e56648.

    Article  CAS  Google Scholar 

  18. Vallejo C, Montesinos P, Polo M, Cuevas B, Morado M, Rosell A, et al. Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. Ann Hematol. 2015;94:947–54.

    Article  CAS  Google Scholar 

  19. Jeong DC, Chung NG, Cho B, Zou Y, Ruan M, Takahashi Y, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2014;99:664–71.

    Article  CAS  Google Scholar 

  20. Suzuki T, Suzuki S, Kobayashi H, Kawasaki Y, Okazuka K, et al. Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations. Int J Hematol. 2016;104:446–53.

    Article  CAS  Google Scholar 

  21. Xie LN, Fang Y, Yu Z, Song NX, Kong FS, Liu XM, et al. Increased immunosuppressive treatment combined with unrelated umbilical cord blood infusion in children with severe aplastic anemia. Cell Immunol. 2014;289:150–4.

    Article  CAS  Google Scholar 

  22. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, et al. Once daily IV busulfan and fludarabine (IV Bu-Flu) compares favorably with IV busulfan and cyclophosphamide (IV BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow transplant. 2008;14:672–84.

    Article  CAS  Google Scholar 

  23. Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socié G, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94:1312–5.

    Article  CAS  Google Scholar 

  24. Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet. 1977;2:1145–8.

    Article  CAS  Google Scholar 

  25. Luo X, Lu HN, Xu B, Wu H, Li B, et al. Efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in severe aplastic anemia patients: a cohort study. Exp Ther Med. 2018;15:1966–74.

    CAS  PubMed  Google Scholar 

  26. Zhang X, Li ZZ, Geng W, Song B, Wan CC. Effects and predictive factors of immunosuppressive therapy combined with umbilical cord blood infusion in patients with severe aplastic anemia. Yonsei Med J. 2018;59:643–51.

    Article  CAS  Google Scholar 

  27. Li Y, Sheng ZX, Niu SN, Ge LF, Ren CA, et al. Rapid and complete reconstitution of autologous haemopoiesis after cord blood infusion in treatment-naive patients with severe aplastic anemia receiving high-dose cyclophosphamide/ATG therapy. Eur J Haematol. 2013;90:45–50.

    Article  CAS  Google Scholar 

  28. Dao AT, Yamazaki H, Takamatsu H, Sugimori C, Katagiri T, et al. Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia. Ann Hematol. 2016;95:771–81.

    Article  CAS  Google Scholar 

  29. Xiao Y, Jiang ZJ, Pang Y, Li L, Gao Y, Xiao HW, et al. Efficacy and safety of mesenchymal stromal cell treatment from related donors for patients with refractory aplastic anemia. Cytotherapy. 2013;15:760–6.

    Article  CAS  Google Scholar 

  30. Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–25.

    Article  CAS  Google Scholar 

  31. Hwang YY, Gill H, Chan TSY, Leung GMK, Cheung CYM, et al. Eltrombopag in the management of aplastic anemia: real-world experience in a non-trial setting. Hematology. 2018;23:399–404.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank all the clinicians involved in the care of these patients and for the collection of data; and we thank Youwen Qin and Xiaorui Wang for performing the chimerism analyses.

Author information

Authors and Affiliations

  1. Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China

    Jieling Jiang, Yu Cai, Liping Wan, Jun Yang & Chun Wang

Authors
  1. Jieling Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liping Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chun Wang.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, J., Cai, Y., Wan, L. et al. Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia. Int J Hematol 111, 360–368 (2020). https://doi.org/10.1007/s12185-019-02807-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02807-7

Keywords

Search

Navigation